ERBB2 and neoplasm: As shown in Figure 2C, combined class I and class II pulsed HER2-DC1 vaccine given twice a week significantly delayed tumor growth in TUBO bearing mice but there was no additive benefit in reducing tumor burden (Figure 2C) compared to class I or class II HER2-DC1 alone as shown in Figures 2A,B.